Key Takeaways

Ta1 is purported to support immune resilience, infection defense, vaccine response, and recovery from immune stress.
The peptide has been studied in humans, but that history is mixed, disease-specific, and often tied to foreign finished products or outdated treatment settings.
The most defensible summary is that Ta1 is a clinically investigated immunomodulatory peptide, not a broadly validated immune-support therapy in the United States.

‍

[FDA, 2024; Wu et al., 2025]

Thymosin Alpha-1 / Ta1: an unapproved-in-the-United-States, investigational 28-amino-acid N-terminally acetylated immunomodulatory peptide; the canonical sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, and the synthetic same-sequence form is commonly called thymalfasin.

Overview

Thymosin alpha-1 sits in a different evidence category from many peptides sold through wellness clinics. It is a real 28-amino-acid peptide with decades of same-molecule human investigation and a synthetic finished product, thymalfasin, marketed in some countries under names such as Zadaxin. But it is not approved by the U.S. Food and Drug Administration for any indication, and foreign product history does not validate a U.S.-compounded free-base vial, acetate vial, nasal spray, or broad immune-support protocol. [FDA, 2024; FDA, 2026; NCATS Inxight Drugs, 2026; Singapore NDF, 2026]

The strongest modern same-molecule efficacy test is not positive. In the 2025 TESTS trial, 1,089 adults with sepsis were included in the modified intention-to-treat analysis, and 28-day mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo; the hazard ratio was 0.99, with no clear evidence of mortality benefit. Earlier sepsis work had suggested a signal, but the larger double-blind Phase 3 result materially lowers confidence in generalized sepsis claims. [Wu et al., 2013; Wu et al., 2025]

Other human evidence is indication-specific and historically uneven. Older hepatitis B trials produced mixed virologic findings; a Phase 3 multicenter study did not outperform placebo on its principal follow-up virologic outcome. In chronic hepatitis C, an adjunctive trial added thymosin alpha-1 to peginterferon and ribavirin without a statistically significant improvement in sustained virologic response. COVID-19 evidence includes a small randomized pilot and observational work, but no robust basis for saying that the peptide treats acute COVID-19, prevents long COVID, or restores immune function. [Chien et al., 1998; Mutchnick et al., 1999; Ciancio et al., 2012; Shehadeh et al., 2023; Wang et al., 2021]

Regulatory posture is cautionary. FDA currently places thymosin-alpha-1 in the section for bulk drug substances whose nominations were withdrawn after previously appearing in Category 2, and states that compounded Ta1 may present immunogenicity risk and peptide-impurity and API-characterization complexity, with inadequate safety information to understand the full extent of risk. At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, members voted 4 yes to 17 no on placing the free base on the 503A Bulks List and 4 yes to 17 no on placing the acetate on the list. [FDA, 2024; FDA, 2026; Federal Register, 2024; Federal Register, 2026]

What it is

Thymosin alpha-1 is an N-terminally acetylated peptide containing 28 amino acids. FDA identifies the free-base sequence as Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. The free base has UNII W0B22ISQ1C, CAS 62304-98-7, molecular formula C129H215N33O55, and molecular weight about 3108.3 g/mol. [FDA, 2024; PubChem, 2026; NCATS Inxight Drugs, 2026]

The peptide was originally isolated from calf thymosin fraction 5 and sequenced in 1977. Later work identified thymosin alpha-1 as a peptide that can be generated from prothymosin-alpha processing. In human physiology, that endogenous relationship helps explain why the molecule sounds "natural." It does not establish that an exogenous synthetic product, at a particular concentration and route, reproduces endogenous regulation or is safe for generalized use. [Goldstein et al., 1977; Sarandeses et al., 2003]

Thymalfasin is the common nonproprietary name for the chemically synthesized same-sequence therapeutic form. Zadaxin is a foreign finished product containing thymalfasin and is listed for subcutaneous use in Singapore. That foreign product has its own manufacturing, excipient, packaging, and regulatory history; it cannot be used as a silent quality bridge for a different U.S. compounded vial or spray. [NCI, 2026; NCATS Inxight Drugs, 2026; Singapore NDF, 2026; FDA, 2024]

Material	What it is	Why it cannot be collapsed into "Ta1"
Prothymosin-alpha	Larger endogenous precursor protein associated with the Ta1 sequence.	Precursor expression and processing do not prove clinical benefit from administered Ta1. [Sarandeses et al., 2003]
Synthetic Ta1 / thymalfasin free base	Chemically synthesized same-sequence peptide; the principal active moiety in the clinical literature.	Clinical findings remain indication-, formulation-, and route-specific. [FDA, 2024; NCI, 2026]
Thymosin alpha-1 acetate	Acetate salt sharing the active peptide moiety.	FDA treats it as a distinct bulk drug substance; free-base data do not automatically settle acetate CMC or safety. [FDA, 2024]
Zadaxin	Foreign finished injectable drug product containing thymalfasin.	Foreign registration is not U.S. FDA approval and does not validate unrelated compounded products. [Singapore NDF, 2026]
Thymosin beta-4 / TB-500	Different thymosin-family molecules with different sequences and development histories.	The shared word "thymosin" is not evidence of molecular or therapeutic equivalence. [FDA, 2024]

How it's proposed to work

The best-supported mechanistic backbone is immune modulation across dendritic-cell, T-cell, and innate-immune signaling rather than one clinically validated receptor pathway. Early work established Ta1 as an immunologically active thymic peptide, and later experimental studies mapped multiple effects on immune-cell maturation and signaling. [Goldstein et al., 1977; Yao et al., 2007]

One mechanistic anchor comes from dendritic cells. In experimental antifungal systems, Ta1 activated dendritic cells through Toll-like-receptor-linked signaling and promoted Th1-oriented resistance. In cultured human CD14-positive monocytes, Ta1 influenced dendritic-cell differentiation and functional maturation. [Romani et al., 2004; Yao et al., 2007]

A second anchor is immune regulation rather than pure stimulation. Romani and colleagues reported that Ta1 increased dendritic-cell tryptophan catabolism through indoleamine 2,3-dioxygenase-related pathways and helped establish a regulatory environment balancing inflammation and tolerance. That is almost the opposite of the simplistic "turns immunity up" narrative. [Romani et al., 2006]

The most defensible mechanism language is therefore conditional and context-specific: Ta1 has been reported to modulate dendritic-cell maturation, Toll-like-receptor-associated signaling, T-cell-related immune responses, and regulatory tryptophan catabolism pathways in experimental systems. This is still a mechanistic map, not proof that every patient with "low immunity," chronic inflammation, recurrent infection, fatigue, or aging-related immune change will benefit from exogenous Ta1. [Romani et al., 2004; Romani et al., 2006; Yao et al., 2007]

Common forms in circulation

FDA's December 2024 evaluation separately considered thymosin alpha-1 free base and thymosin alpha-1 acetate as bulk drug substances proposed for a subcutaneous injectable product. The nomination proposed a 3 mg/mL solution, but FDA found that the nomination did not explain how that concentration would be achieved in light of reported water-solubility limits and did not provide adequate support for the strength. [FDA, 2024]

Current U.S.-facing channels describe subcutaneous injections, home-delivered peptide subscriptions, and intranasal sprays. FDA's own market search identified injections and nasal sprays, including products marketed as 3 mg and 10 mg sprays; one site falsely called a compounded Ta1 injection FDA-approved. [FDA, 2024]

Names and aliases

Scientific and regulatory names include thymosin alpha-1, thymosin alpha 1, Ta1, Talpha1, thymalfasin, thymosin-alpha-1 free base, thymosin-alpha-1 acetate, and the sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Zadaxin is a foreign brand name. Do not confuse Ta1 with thymosin beta-4, TB-500, thymosin fraction 5, or other thymic extracts. [FDA, 2024; PubChem, 2026; NCATS Inxight Drugs, 2026]

Regulatory status

Ta1 has no FDA-approved indication in the United States. FDA's orphan-drug database records a March 6, 2000 orphan designation for thymalfasin in hepatocellular carcinoma, but the same record explicitly states that it is not FDA-approved for the orphan indication. [FDA, 2000]

FDA's current compounding-risk page places thymosin-alpha-1 under "bulk drug substances nominated but withdrawn," a section containing substances previously in Category 2 whose nominations were withdrawn. The agency states that compounded Ta1 may present significant immunogenicity risk for certain routes and may create peptide-impurity and API-characterization complexity; FDA says the safety information is inadequate to understand the full extent of potential safety issues. [FDA, 2026]

In a December 2020 warning letter, FDA cited a seller marketing Ta1 for "immune health" and COVID-19 with claims that it restored the immune system and reduced COVID-19 mortality. FDA treated the products as unapproved and misbranded drugs. [FDA, 2020]

FDA reviewed Ta1 free base and Ta1 acetate for proposed subcutaneous use in hepatitis B, hepatitis C, HIV, COVID-19, vaccine adjuvant use, melanoma, hepatocellular carcinoma, non-small-cell lung cancer, sepsis, infections after hematopoietic stem-cell transplantation, COPD, and ME/CFS. FDA's overall effectiveness conclusion was that evidence was lacking across the reviewed uses, with recurring problems including small samples, single-arm or retrospective designs, outdated comparator therapy, unclear clinical endpoints, and no demonstrated advantage over current standard care. The committee voted 4 yes, 17 no on the free base, and 4 yes, 17 no on the acetate. [FDA, 2024; Federal Register, 2024]

Ta1 is not scheduled for the July 23-24, 2026 PCAC meeting. That later agenda covers BPC-157, KPV, TB-500, MOTS-C, emideltide/DSIP, Semax, and Epitalon; its relevant PCAC review already occurred in 2024. [FDA, 2026; Federal Register, 2026]

Safety

The human safety record is larger than for many experimental peptides, but it is not a blank check. FDA found that most clinical studies reported Ta1 as generally tolerated, with local irritation, redness, or discomfort at the injection site as the most common adverse reactions. Foreign-label information also describes infrequent rash, edema-related symptoms, and other events. Those findings belong to the studied products, concentrations, routes, populations, and durations; they do not establish safety for a different compounded formulation or long-term wellness use. [FDA, 2024]

FDA also identified context-specific safety signals, including transient alanine-aminotransferase flares in chronic hepatitis B, thyroid-stimulating-hormone abnormalities in interferon-containing regimens, and serious events in a very small post-transplant experience. In one HSCT-related case, fatal immune hemolytic anemia occurred after donor-lymphocyte infusion and Ta1, with uncertain attribution. [FDA, 2024; Perruccio et al., 2010]

Human evidence, by use case

Ta1 is unusual because the question is not "are there any human studies?" There are many. The problem is that they span different diseases, eras, background therapies, products, routes, and endpoints. FDA's 2024 review found no adequate effectiveness basis for the proposed compounded uses.

Use case	Strongest evidence	Bottom-line result
Sepsis	TESTS, multicenter double-blind Phase 3; ETASS earlier single-blind RCT.	TESTS found 28-day mortality of 23.4% vs 24.1% and no clear benefit; earlier signal did not confirm in the larger trial. [Wu et al., 2013; Wu et al., 2025]
Chronic hepatitis B	Older randomized trials and a multicenter Phase 3 study.	Some early studies reported delayed virologic responses, but Phase 3 follow-up HBV-DNA clearance was similar to placebo. [Chien et al., 1998; Mutchnick et al., 1999]
Chronic hepatitis C	Pilot monotherapy and adjunctive interferon-era trials.	The later peginterferon/ribavirin adjunctive study did not significantly improve sustained virologic response. [Andreone et al., 1996; Ciancio et al., 2012]
COVID-19	Small randomized open-label pilot plus observational and immune-cell studies.	The pilot did not establish a statistically clear clinical recovery benefit; a separate study did not show restoration of CD4/CD8 counts. [Shehadeh et al., 2023; Wang et al., 2021]
Vaccine response	Small 1989 influenza vaccine study; recruiting Phase 1 COVID-booster study in older adults.	Older antibody-response signal is hypothesis-generating; the current study is safety/dose-finding and not yet reported. [Gravenstein et al., 1989]
Cancer adjunct	Adjunctive melanoma and HCC trials in historical regimens.	Some studies explored combination immunotherapy or chemoembolization settings; results do not establish standalone antitumor efficacy. [Maio et al., 2010; Gish et al., 2009]
Post-HSCT infection	Very small Phase I/II experience.	Feasibility and immune-reconstitution interest only, with serious safety uncertainty in a highly complex population. [Perruccio et al., 2010]

FDA did not identify clinical studies supporting Ta1 for ME/CFS and did not find an adequate basis for the broader reviewed uses. Current clinic pages nonetheless extend Ta1 into recurrent illness, chronic inflammation, fatigue, anti-aging, longevity, autoimmune conditions, and generalized wellness. Those are market expansions, not clinically established indications. [FDA, 2024]

Purported benefits, by evidence

Purported benefit	Tagged evidence strength	What the evidence supports	What it does not support
General immune support / resilience	Mechanistic	Ta1 has experimentally documented effects on dendritic-cell maturation, T-cell-related pathways, and immune regulation.	"Boosts immunity," fewer infections, faster recovery, or a generalized immune-deficiency treatment claim. [Romani et al., 2004; Romani et al., 2006; Yao et al., 2007]
Sepsis survival	Clinical trial — negative confirmatory result	Earlier ETASS work suggested a mortality signal; the larger double-blind TESTS trial found no clear reduction in 28-day mortality.	"Reduces sepsis mortality," "improves survival," or routine sepsis use. [Wu et al., 2013; Wu et al., 2025]
Chronic hepatitis B	Older clinical trials, mixed	Some older randomized studies reported delayed virologic responses, but the Phase 3 evidence did not show a clear advantage over placebo.	Current HBV treatment claims or substitution for approved antivirals. [Chien et al., 1998; Mutchnick et al., 1999]
Acute COVID-19 / long COVID	Small clinical trial plus observational	A small randomized pilot explored hospitalized patients with hypoxemia and lymphocytopenia; another study examined lymphocyte counts.	Treatment, mortality reduction, immune restoration, antiviral defense, or prevention of long COVID. [Shehadeh et al., 2023; Wang et al., 2021]
Cancer adjunct / immune surveillance	Adjunctive clinical trials in historical regimens	Melanoma and HCC studies show that Ta1 has been explored as an adjunct in oncology.	"Anti-cancer peptide," "prevents recurrence," "improves tumor surveillance," or monotherapy claims. [Maio et al., 2010; Gish et al., 2009]
Healthy aging / immunosenescence / fatigue	Commercial plus mechanistic extrapolation	Age-related thymic decline makes the story intuitive, and an older-adult vaccine study is ongoing.	Anti-aging, longevity, restored thymic output, improved energy, ME/CFS treatment, or fewer illnesses. [FDA, 2024]

Key literature

Goldstein AL, Low TLK, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. Foundational identity and immunologic activity.

Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. IDO/tryptophan catabolism and tolerance-related biology.

Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. Earlier mortality and immune-function signal.

Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. Strongest modern same-molecule efficacy test; no clear 28-day mortality benefit.

Shehadeh F, Benitez G, Mylona EK, et al. A Pilot Trial of Thymalfasin (Thymosin alpha-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis. 2023;227(2):226-235. Preliminary hospitalized-COVID safety and immune-response information.

References

U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals: Thymalfasin; designated March 6, 2000 for treatment of hepatocellular carcinoma; not FDA approved for orphan indication.
U.S. Food and Drug Administration. Paradigm RE LLC - Warning Letter 612014: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19). December 7, 2020.
U.S. Food and Drug Administration. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document for Thymosin Alpha-1 Related Bulk Drug Substances.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
National Center for Biotechnology Information. PubChem Compound Summary for CID 16130571, Thymalfasin.
Government of Singapore, National Drug Formulary. Thymosin Alpha 1 [Zadaxin]; subcutaneous product listing.
Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS). Crit Care. 2013;17(1):R8.
Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS). BMJ. 2025;388:e082583.

Thymosin Alpha-1 (Ta1)